Search

Alan rejoined the LMB in 2010, where he continued his work on protein folding, misfolding and disease, concentrating on the tumour suppressor p53 until the end of 2017. ... n. Cancer is a disease of mutation, and the most commonly mutated protein by far

{"id":61,"date":"2012-06-25T10:03:42","date_gmt":"2012-06-25T10:03:42","guid":{"rendered":"http://www2.mrc-lmb.cam.ac.uk/wordpress/?page_id=61"},"modified":"2024-05-20T14:39:16","modified_gmt":"2024-05-20T13:39:16","slug":"protein-and-nucleic-acid-ch

can bind to and deactivate an enzyme that controls the stability of the p53 tumour suppressor protein. ... This deactivation allows p53 to be turned on, putting the brakes on cancer growth.

nAlan will continue to lead his research on the p53 tumour suppressor protein at the LMB with an MRC programme grant for the next five years.

n. Professor Sir Alan Fersht, FRS, from the PNAC Division of LMB, has been awarded an Advanced ERC Grant of u20ac1.5m for his project u201cTumour suppressor p53: structure, stability and ... 70% of human cancers have p53 directly inactivated by mutation.

{"id":18741,"date":"2020-08-04T17:10:07","date_gmt":"2020-08-04T16:10:07","guid":{"rendered":"https://www2.mrc-lmb.cam.ac.uk/?p=18741"},"modified":"2020-08-04T17:10:09","modified_gmt":"2020-08-04T16:10:09","slug":"alan-fersht-and-marta-zlatic-win-roy